Experimental Drug Earns Orphan Drug Designation for Hypothalamic Obesity
source: pixabay.com

Experimental Drug Earns Orphan Drug Designation for Hypothalamic Obesity

According to a press release published on Globe Newswire, the biopharmaceutical company Saniona has announced recently that its investigational therapy Tesomet has recently earned Orphan Drug designation from the US…

Continue Reading Experimental Drug Earns Orphan Drug Designation for Hypothalamic Obesity
Promising Data from Phase 2 VX-864 Study for A1AD, Despite Discontinuation
source: pixabay.com

Promising Data from Phase 2 VX-864 Study for A1AD, Despite Discontinuation

Medical studies are crucial players in the journey to develop new and more efficacious treatment options for patients with rare diseases. On June 10, 2021, Vertex Pharmaceuticals Incorporated ("Vertex") shared…

Continue Reading Promising Data from Phase 2 VX-864 Study for A1AD, Despite Discontinuation